CBER Director Goodman Fits New Center Mission, Offers Continuity For Staff
Executive Summary
The elevation of Center for Biologics Evaluation & Research Deputy Director Jesse Goodman, MD, to the top position in the center emphasizes continuity during a time of change for FDA's biologics staff
You may also be interested in...
FDA’s Goodman Is Rising Star Within Agency As Obama Team Coalesces
FDA's top biologics review manager Jesse Goodman is taking on a more prominent role within the agency and HHS as FDA realigns its management in anticipation of the arrival of Commissioner-designate Margaret Hamburg and her principal deputy Joshua Sharfstein
FDA’s Goodman Is Rising Star Within Agency As Obama Team Coalesces
FDA's top biologics review manager Jesse Goodman is taking on a more prominent role within the agency and HHS as FDA realigns its management in anticipation of the arrival of Commissioner-designate Margaret Hamburg and her principal deputy Joshua Sharfstein
CBER completes top level turnover
FDA Center for Biologics Evaluation & Research Deputy Director for Operations Mark Elengold will retire in June. His departure completes CBER's top level turnover after FDA moved the review of therapeutic biologics to the Center for Drug Evaluation & Research. CBER Director Jesse Goodman was elevated from the position of deputy director for medicine following the departure of previous director Kathryn Zoon (1"The Pink Sheet" Dec. 23, 2002, p. 3). Elengold featured prominently during the debate on the third Prescription Drug User Fee Act, expressing FDA's desire for a more predictable revenue stream (2"The Pink Sheet" June 12, 2000, p. 9)...